Top

Published in:

01-11-2011 | Clinical trial

Young age is associated with ipsilateral breast tumor recurrence after breast conserving surgery and radiation therapy in patients with HER2-positive/ER-negative subtype

Authors: Hee Jeong Kim, Wonshik Han, On Vox Yi, Hee Chul Shin, Soo-Kyung Ahn, Beom Seok Koh, Hyeong-Gon Moon, Jong Han You, Byung Ho Son, Sei Hyun Ahn, Dong-Young Noh

Published in: Breast Cancer Research and Treatment | Issue 2/2011

Abstract

Young breast cancer patients are more likely than old patients to experience ipsilateral breast tumor recurrence (IBTR) after breast conserving surgery (BCS). However, the pathological processes underlying this relationship have not been elucidated. We investigated the effect of young age on IBTR in a Korean cohort of women with different molecular subtypes of breast cancer. We analyzed data of 2,102 consecutive breast cancer patients who underwent BCS and post-surgical radiation therapy (RT) at two Korean institutions between 2000 and 2005. Patients were classified as young (≤40 years; N = 513) or old (>40 years; N = 1,589). Breast cancer subtype was determined by estrogen receptor (ER), progesterone receptor (PR), and HER2. Median follow-up duration was 61 months. The 5-year IBTR rate was 3.4% in young patients and 1.1% in old patients (P < 0.001). Univariate analysis indicated that IBTR rate in young patients with luminal A and HER2 subtypes was significantly greater than in old patients with these subtypes (P = 0.015 and P < 0.001, respectively). Multivariate analysis, which used luminal A subtype in old patients as reference, indicated that HER2 subtype in young patients was associated with increased risk of IBTR (hazard ratio, HR = 12.24; 95% CI: 2.54–57.96). Among old patients, HER2 subtype was not associated with increased IBTR. In conclusion, young women had a higher rate of IBTR after BCS and RT than old women. This difference is mainly among women with HER2 subtype. Aggressive local control and adjuvant therapy should be considered for young women with HER2 subtype breast cancer.

Colleoni M, Rotmensz N, Peruzzotti G, Maisonneuve P, Orlando L, Ghisini R et al (2006) Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease. Ann Oncol 17:1497–1503PubMedCrossRef

Han W, Kim SW, Park IA, Kang D, Youn YK, Oh SK et al (2004) Young age: an independent risk factor for disease-free survival in women with operable breast cancer. BMC Cancer 4:82PubMedCrossRef

O’Rourke MT, Ellison PT (1993) Age and prognosis in premenopausal breast cancer. Lancet 342:60PubMedCrossRef

Han W, Kang SY (2010) Relationship between age at diagnosis and outcome of premenopausal breast cancer: age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer. Breast Cancer Res Treat 119:193–200PubMedCrossRef

Ahn SH, Son BH, Kim SW, Kim SI, Jeong J, Ko SS et al (2007) Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea—a report from the Korean Breast Cancer Society. J Clin Oncol 25:2360–2368PubMedCrossRef

Bollet MA, Sigal-Zafrani B, Mazeau V, Savignoni A, de la Rochefordiere A, Vincent-Salomon A et al (2007) Age remains the first prognostic factor for loco-regional breast cancer recurrence in young (<40 years) women treated with breast conserving surgery first. Radiother Oncol 82:272–280PubMedCrossRef

Jones HA, Antonini N, Hart AA, Peterse JL, Horiot JC, Collin F et al (2009) Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial. J Clin Oncol 27:4939–4947PubMedCrossRef

Bartelink H, Horiot JC, Poortmans P, Struikmans H, Van den Bogaert W, Barillot I et al (2001) Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 345:1378–1387PubMedCrossRef

Botteri E, Bagnardi V, Rotmensz N, Gentilini O, Disalvatore D, Bazolli B et al (2010) Analysis of local and regional recurrences in breast cancer after conservative surgery. Ann Oncol 21:723–728PubMedCrossRef

10.

Zhou P, Gautam S, Recht A (2007) Factors affecting outcome for young women with early stage invasive breast cancer treated with breast-conserving therapy. Breast Cancer Res Treat 101:51–57PubMedCrossRef

11.

Komoike Y, Akiyama F, Iino Y, Ikeda T, Akashi-Tanaka S, Ohsumi S et al (2006) Ipsilateral breast tumor recurrence (IBTR) after breast-conserving treatment for early breast cancer: risk factors and impact on distant metastases. Cancer 106:35–41PubMedCrossRef

12.

Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752PubMedCrossRef

13.

Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874PubMedCrossRef

14.

Albert JM, Gonzalez-Angulo AM, Guray M, Sahin A, Strom EA, Tereffe W et al (2010) Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a, bN0 breast cancer. Int J Radiat Oncol Biol Phys 77:1296–1302PubMedCrossRef

15.

Voduc KD, Cheang MCU, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H (2010) Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28:1684–1691PubMedCrossRef

16.

Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL et al (2008) Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 26:2373–2378PubMedCrossRef

17.

Antonini N, Jones H, Horiot JC, Poortmans P, Struikmans H, Van den Bogaert W et al (2007) Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881-10882. Radiother Oncol 82:265–271PubMedCrossRef

18.

Anders CK, Fan C, Parker JS, Carey LA, Blackwell KL, Klauber-DeMore N et al (2011) Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes? J Clin Oncol 29:e18–e20PubMedCrossRef

19.

Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y et al (2008) Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 26:3324–3330PubMedCrossRef

20.

Cil T, Fishell E, Hanna W, Sun P, Rawlinson E, Narod SA et al (2009) Mammographic density and the risk of breast cancer recurrence after breast-conserving surgery. Cancer 115:5780–5787PubMedCrossRef

21.

Boyd NF, Rommens JM, Vogt K, Lee V, Hopper JL, Yaffe MJ et al (2005) Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol 6:798–808PubMedCrossRef

22.

Harvey JA (2004) Quantitative assessment of percent breast density: analog versus digital acquisition. Technol Cancer Res Treat 3:611–616PubMed

23.

Guo YP, Martin LJ, Hanna W, Banerjee D, Miller N, Fishell E et al (2001) Growth factors and stromal matrix proteins associated with mammographic densities. Cancer Epidemiol Biomark Prev 10:243–248

24.

van Gils CH, Otten JD, Verbeek AL, Hendriks JH (1998) Mammographic breast density and risk of breast cancer: masking bias or causality? Eur J Epidemiol 14:315–320PubMedCrossRef

25.

Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J et al (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24:5652–5657PubMedCrossRef

26.

Millar EKA, Graham PH, O’Toole SA, McNeil CM, Browne L, Morey AL et al (2009) Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol 27:4701–4708PubMedCrossRef

27.

Sartor CI (2003) Epidermal growth factor family receptors and inhibitors: radiation response modulators. Semin Radiat Oncol 13:22–30PubMedCrossRef

28.

Pietras RJ, Poen JC, Gallardo D, Wongvipat PN, Lee HJ, Slamon DJ (1999) Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 59:1347–1355PubMed

29.

Rao GS, Murray S, Ethier SP (2000) Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor. Int J Radiat Oncol Biol Phys 48:1519–1528PubMedCrossRef

30.

No M, Choi EJ, Kim IA (2009) Targeting HER2 signaling pathway for radiosensitization: alternative strategy for therapeutic resistance. Cancer Biol Ther 8:2351–2361PubMedCrossRef

31.

Sambade MJ, Camp JT, Kimple RJ, Sartor CI, Shields JM (2009) Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf>MEK>ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK. Radiother Oncol 93:639–644PubMedCrossRef

32.

Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A et al (2002) Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347:1227–1232PubMedCrossRef

33.

Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER et al (2002) Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347:1233–1241PubMedCrossRef

34.

Coulombe G, Tyldesley S, Speers C, Paltiel C, Aquino-Parsons C, Bernstein V et al (2007) Is mastectomy superior to breast-conserving treatment for young women? Int J Radiat Oncol Biol Phys 67:1282–1290PubMedCrossRef

35.

Neuschatz AC, DiPetrillo T, Safaii H, Price LL, Schmidt-Ullrich RK, Wazer DE (2003) Long-term follow-up of a prospective policy of margin-directed radiation dose escalation in breast-conserving therapy. Cancer 97:30–39PubMedCrossRef

36.

Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–1684PubMedCrossRef

37.

Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–1672PubMedCrossRef

38.

Koukourakis MI, Giatromanolaki A, Galazios G, Sivridis E (2003) Molecular analysis of local relapse in high-risk breast cancer patients: Can radiotherapy fractionation and time factors make a difference? Br J Cancer 88:711–717PubMedCrossRef

39.

Colleoni M, Rotmensz N, Peruzzotti G, Maisonneuve P, Viale G, Renne G et al (2004) Minimal and small size invasive breast cancer with no axillary lymph node involvement: the need for tailored adjuvant therapies. Ann Oncol 15:1633–1639PubMedCrossRef

40.

Zellars RC, Hilsenbeck SG, Clark GM, Allred DC, Herman TS, Chamness GC et al (2000) Prognostic value of p53 for local failure in mastectomy-treated breast cancer patients. J Clin Oncol 18:1906–1913PubMed

Title: Young age is associated with ipsilateral breast tumor recurrence after breast conserving surgery and radiation therapy in patients with HER2-positive/ER-negative subtype
Authors: Hee Jeong Kim
Wonshik Han
On Vox Yi
Hee Chul Shin
Soo-Kyung Ahn
Beom Seok Koh
Hyeong-Gon Moon
Jong Han You
Byung Ho Son
Sei Hyun Ahn
Dong-Young Noh
Publication date: 01-11-2011
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-011-1736-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2011

Long-term course of pain in breast cancer survivors: a 4-year longitudinal study

P53 genotype as a determinant of ER expression and tamoxifen response in the MMTV-Wnt-1 model of mammary carcinogenesis

Correlation between docetaxel-induced skin toxicity and the use of steroids and H2 blockers: a multi-institution survey

CG0006, a novel histone deacetylase inhibitor, induces breast cancer cell death via histone-acetylation and chaperone-disrupting pathways independent of ER status

Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups

Effect of false-positives and women’s characteristics on long-term adherence to breast cancer screening

Keynote webinar | Spotlight on antibody–drug conjugates in cancer